Overview

Study to Learn More About the Effect of Itraconazole (ITZ) Given Repeatedly by Mouth on the Way How the Study Drug BAY1902607 Given One Time by Mouth Acts in the Human Body of Healthy Male Participants

Status:
Completed
Trial end date:
2019-05-23
Target enrollment:
0
Participant gender:
Male
Summary
BAY1902607 is a new type of drug under clinical development for different conditions including the treatment of endometriosis, i.e. a condition where the tissue that usually grows inside the womb grows outside of the womb. Itraconazole (ITZ) is an approved drug often used for the treatment of fungal infections and possibly inhibits the breakdown of BAY1902607. In this clinical study, BAY1902607 is given alone by mouth or in combination with ITZ. Researchers want to learn more how quickly and to what extent the study drug BAY1902607 given by mouth to healthy male participants is absorbed by the human body, reaches the blood stream and is excreted again. In addition they want to find out whether the elimination of the study drug BAY1902607 is influenced by ITZ given at the same time.
Phase:
Phase 1
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Bayer
Treatments:
Hydroxyitraconazole
Itraconazole
Criteria
Inclusion Criteria:

- Healthy, male adults

- Body mass index ≥ 18 and ≤ 30.0 kg/m²

- Body weight ≥ 50 kg

Exclusion Criteria:

- Known or suspected allergy or hypersensitivity to BAY1902607, itraconazole or any of
their excipients

- Contraindications to itraconazole (symptoms or history of ventricular dysfunction,
heart failure, liver disease).

- Any use of systemic or topically active medication or herbal remedies, prescription or
non-prescription, within 1 week prior to the first drug administration or during the
trial until follow-up (occasional use of ibuprofen is permissible). Particularly, this
includes drugs that might affect the pharmacokinetics (PK) of BAY1902607, e.g.
laxatives, loperamide, metoclopramide, antacids, H2-receptor antagonists, CYP3A4
inhibitors or inducers.